Hamilton Thorne Ltd.
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Ekaterina Torchilin MBA,
- Sector
- Healthcare
- Industry
- Medical - Devices
- Address
- 100 Cummings Center Beverly MA United States of America 01915
- IPO Date
- Feb 23, 2010
- Website
- hamiltonthorne.ltd
- Similar Companies
- Business
- Hamilton Thorne Ltd. (HTLZF) provides precision instruments, consumables, software, and services to the assisted reproductive technologies (ART), research, and cell biology markets. The company offers a portfolio of products including micromanipulation systems such as the LYKOS laser system and the Saturn 5 laser system; imaging solutions like the PRIME microscope and the ESCORT embryo incubator monitoring system; disposable products comprising microplates, pipettes, and embryo handling media; and services encompassing equipment maintenance, training, and installation support. These offerings cater to fertility clinics, research institutions, and pharmaceutical companies focused on stem cell and developmental biology applications. Founded in 2010 and headquartered in Beverly, Massachusetts, Hamilton Thorne operates globally across North America, Europe, Asia, and Australia, with manufacturing facilities in the United States and distribution networks serving over 50 countries. The company serves key segments including in vitro fertilization (IVF), preimplantation genetic testing, and cryopreservation, targeting end-users such as reproductive endocrinologists, embryologists, and academic researchers. In recent developments, Hamilton Thorne has pursued strategic growth through acquisitions, including the 2023 purchase of Gynetics, expanding its endoscopy portfolio for gynecological procedures, and a partnership with CooperSurgical in 2024 to enhance ART workflow integration. The company also launched the GOBI imaging platform in early 2025, improving embryo selection accuracy with AI-driven time-lapse analysis, and secured a CAD 15 million funding round in late 2024 to support R&D in automated cell handling technologies. These initiatives reflect Hamilton Thorne's shift toward integrated digital solutions amid rising global demand for fertility treatments.
Hamilton Thorne (CVE:HTL) Shares Up 4.3% – What’s Next?
Astorg Completes Take Private of Hamilton Thorne and Concurrent Acquisition of Cook Medical Reproductive Health
Hamilton Thorne Announces Closing of Going Private Transaction
Hamilton Thorne Reports Revenue for the Quarter and Nine Months Ended September 30, 2024
Hamilton Thorne Provides Update on Going Private Transaction
Hamilton Thorne Announces Shareholder Approval of Going Private Transaction
Hamilton Thorne Announces Mailing of Meeting Materials and Receipt of Interim Order in Respect of Going Private Transaction
Hamilton Thorne Reports Revenue for the Quarter and Six Months Ended June 30, 2024, and Confirms Annual Guidance
Hamilton Thorne to Release Q2 2024 Financial Results on August 14, 2024
Hamilton Thorne Announces Agreement to be Acquired by Astorg for CAD$2.25 Per Share in Cash
Hamilton Thorne Announces Voting Results of 2024 Annual Meeting
Hamilton Thorne Ltd. (HTLZF) Q1 2024 Earnings Call Transcript
Hamilton Thorne Reports Record Revenue and EBITDA for the Quarter Ended March 31, 2024, and Confirms Annual Guidance
Hamilton Thorne to Announce Q1 2024 Financial Results and Hold Conference Call on May 14, 2024
Hamilton Thorne Ltd. to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference
Hamilton Thorne Ltd. to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference
Hamilton Thorne Ltd. (HTLZF) Q4 2023 Earnings Call Transcript
Hamilton Thorne Reports Record Revenue and EBITDA for the Quarter and Year Ended December 31, 2023
Hamilton Thorne to Announce Q4 and Full Year 2023 Financial Results and Hold Conference Call on March 27, 2024
Hamilton Thorne Appoints Dr. Ekaterina (Kate) Torchilin as President and CEO